Myeloma Therapeutics Reference: This is not to meant to be an exhaustive list but a guide to key therapies.
Classes of Myeloma Drugs Overview Immunomodulatory Agents (IMiDs)
Thalidomide (Thalomid®)
Proteasome Inhibitors (PI's)
Bortezomib (Velcade®)
Monoclonal Antibodies (mAbs)
Daratumumab (Darzalex® and Darzalex Faspro®) Target: CD38
Other
Idecaptagene vicleucel (ABECMA®) Target: BCMA
Teclistamab (TECVAYLI®) Target: BCMA
Venetoclax (Venclexta®)* for t(11;14) *Not yet approved in myeloma
Ciltacaptagene autoleucel (CARVYKTI® ) Target: BCMA
Talquetamab (TALVEY®) Target: GPRC5D
Infection Prevention: Acyclovir, Valacyclovir; Levofloxacin, SMX-TMP; IVIG
Bendamustine (Treanda®)
Elranatamab (ELREXFIO™) Target: BCMA
Pamidronate Infection Prevention:SM X-TMP or sulfamethoxaz oletrimethoprim
Steroids: Dexamethasone (Decadron®) Prednisone (Deltasone®)
linvoseltamab (LYNOZYFIC™ ) Target: BCMA CD3
Infection Prevention: IVIG, or intravenous immunogloulin
Melphalan (Alkeran®)
XPO1 Inhibitors
Selinexor (Xpovio®) MOA: XPO1 Inhibitor
Belantamab mafodotin (Blenrep®)* Target: BCMA
CELMoDs
Mezigdomide* *Not yet approved in myeloma ZENBEXUS™ (iberdomide)
Lenalidomide (Revlimid®)
Pomalidomide (Pomalyst®)
Carfilzomib (Kyprolis®)
Ixazomib (Ninlaro®)
Elotuzumab (Empliciti®) Target: SLAM F7
Isatuximab (Sarclisa® ) Target: CD38
CAR (Chimeric Antigen Receptor) TCell Therapy
Bispecific Antibodies (BiSAb)
Cytotoxic/ Steroids
Antibody Drug Conjugate (ADC)
Cyclophosphamide (Cytoxan®)
*FDA accelerated approval of iberdomide in combination with Darzalex and dexamethasone for RRMM
Cevostamab* Target: FcRH5 *Not yet approved in
Supportive Care Bone strengthener: (Aredia®) Zoledronate (Zometa®) Denosumab (Xgeva®)